Dr. Mitchell L. Shiffman, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 496
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
VA license 0101036976
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bon Secours St Marys Hospital Richmond, VA
- Bon Secours St Francis Medical Center Midlothian, VA
- Bon Secours Memorial Regional Medical Center Mechanicsville, VA
- Bon Secours Richmond Community Hospital Richmond, VA
- Mary Immaculate Hospital Newport News, VA
Medical groups
- Bon Secours-Richmond Community Hospital LLC (43 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 496
- Services billed
- 1,230
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 158 | 135 |
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 72 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 113 | 58 |
| New patient office or other outpatient visit, 45-59 minutes | 112 | 112 |
| Measurement of liver stiffness | 82 | 82 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 77 | 76 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 73 | 62 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 65 | 47 |
| New patient office or other outpatient visit, 30-44 minutes | 59 | 59 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 50 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Newport News, VA | 104 |
| Furosemide Other prescribers in Newport News, VA | 87 |
| Xifaxan (rifaximin) Other prescribers in Newport News, VA | 59 |
| Lactulose Other prescribers in Newport News, VA | 42 |
| Epclusa (sofosbuvir/velpatasvir) | 39 |
| Pantoprazole Sodium Other prescribers in Newport News, VA | 34 |
| Mycophenolate Mofetil Other prescribers in Newport News, VA | 31 |
| Ursodiol Other prescribers in Newport News, VA | 28 |
| Oxycodone Hcl Other prescribers in Newport News, VA | 27 |
| Cyproheptadine Hcl Other prescribers in Newport News, VA | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 182 payments worth $193,208 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $56,587 |
|---|---|
| Novo Nordisk Inc | $44,635 |
| Gilead Sciences, Inc. | $26,965 |
| Mirum Pharmaceuticals, Inc. | $25,948 |
| Madrigal Pharmaceuticals | $19,760 |
| Intercept Pharmaceuticals, Inc. | $7,569 |
| Fujifilm Healthcare Americas Corporation | $4,983 |
| AstraZeneca Pharmaceuticals LP | $3,344 |
| Compensation for services other than consulting (speaking, faculty) | $128,195 |
|---|---|
| Consulting Fee | $31,385 |
| Travel and Lodging | $24,306 |
| Food and Beverage | $7,049 |
| Honoraria | $1,500 |
| Education | $774 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,520 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $11,040 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $10,557 |
| Novo Nordisk Inc Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $6,476 |
| Gilead Sciences, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4264030;AHM;10015847 | $6,440 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $6,200 |
| Madrigal Pharmaceuticals Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,993 |
| Ipsen Biopharmaceuticals, Inc Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,967 |
All 107 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Mirum Pharmaceuticals, Inc. Dec 15, 2025 | Consulting Fee Livmarli · Alagille syndrome | $963 |
| Novo Nordisk Inc Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Dec 2, 2025 | Travel and Lodging Wegovy · Obesity · travel to Winchester, VA · in-kind | $1,004 |
| Gilead Sciences, Inc. Dec 2, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Charlotte, NC · in-kind Company’s description;4264425;AHM;10015847 | $36.00 |
| Gilead Sciences, Inc. Dec 2, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Charlotte, NC · in-kind Company’s description;4264308;AHM;10015847 | $21.42 |
| Gilead Sciences, Inc. Nov 24, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Charlotte, NC · in-kind Company’s description;4327658;AHM;10015847 | $682 |
| Gilead Sciences, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4264030;AHM;10015847 | $6,440 |
| Ipsen Biopharmaceuticals, Inc Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,967 |
| Ipsen Biopharmaceuticals, Inc Nov 20, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Roanoke, VA · in-kind | $1,333 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Charlotte, NC · in-kind Company’s description;4264082;AHM;10015847 | $781 |
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $5,103 |
| Novo Nordisk Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Nov 12, 2025 | Travel and Lodging Wegovy · Obesity · travel to Charlotte, NC · in-kind | $867 |
| Novo Nordisk Inc Nov 12, 2025 | Travel and Lodging Wegovy · Obesity · travel to Charlotte, NC · in-kind | $827 |
| Novo Nordisk Inc Nov 12, 2025 | Travel and Lodging Wegovy · Obesity · travel to Charlotte, NC · in-kind | $21.42 |
| Ipsen Biopharmaceuticals, Inc Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Bylvay · Gastroenterology | $2,295 |
| Novo Nordisk Inc Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $6,476 |
| Novo Nordisk Inc Oct 30, 2025 | Travel and Lodging Wegovy · Obesity · travel to Falls Church, VA · in-kind | $868 |
| Ipsen Biopharmaceuticals, Inc Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,131 |
| Mirum Pharmaceuticals, Inc. Oct 15, 2025 | Consulting Fee Livmarli · Alagille syndrome | $3,080 |
| Mirum Pharmaceuticals, Inc. Oct 15, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Charlotte, NC | $781 |
| Mirum Pharmaceuticals, Inc. Oct 15, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Charlotte, NC | $42.36 |
| Mirum Pharmaceuticals, Inc. Oct 15, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Charlotte, NC | $38.94 |
| Mirum Pharmaceuticals, Inc. Oct 15, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Charlotte, NC | $32.00 |
| Mirum Pharmaceuticals, Inc. Oct 15, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Charlotte, NC | $21.42 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,520 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $414 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $382 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $221 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $21.70 |
| Mirum Pharmaceuticals, Inc. Oct 4, 2025 | Consulting Fee Livmarli · Alagille syndrome | $2,600 |
| Mirum Pharmaceuticals, Inc. Oct 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Boston, MA | $459 |
| Mirum Pharmaceuticals, Inc. Oct 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Boston, MA | $40.00 |
| Mirum Pharmaceuticals, Inc. Oct 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Boston, MA | $39.49 |
| Mirum Pharmaceuticals, Inc. Oct 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Boston, MA | $21.42 |
| Gilead Sciences, Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4256885;AHM;10015847 | $3,790 |
| Mirum Pharmaceuticals, Inc. Sep 17, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to West Hartford, CT | $392 |
| Mirum Pharmaceuticals, Inc. Sep 17, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to West Hartford, CT | $277 |
| Mirum Pharmaceuticals, Inc. Sep 17, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to West Hartford, CT | $275 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC Sep 15, 2025 | Consulting Fee XIFAXAN · Gastroenterology | $500 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Consulting Fee Livmarli · Alagille syndrome | $3,080 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $516 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $462 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $275 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $43.54 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $40.00 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $25.08 |
| Mirum Pharmaceuticals, Inc. Sep 10, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Baltimore, MD | $23.52 |
| Eisai Inc. Aug 28, 2025 | Education Lenvima · Oncology | $58.50 |
| Eisai Inc. Aug 25, 2025 | Education Lenvima · Oncology | $58.50 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $404 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $244 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $232 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $76.00 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $21.42 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4285122;VEM US;10015847 | $5,000 |
| Gilead Sciences, Inc. Jun 7, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4285231;VEM US;10015847 | $522 |
| Gilead Sciences, Inc. Jun 7, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4285462;VEM US;10015847 | $511 |
| Gilead Sciences, Inc. Jun 7, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285219;VEM US;10015847 | $37.61 |
| Gilead Sciences, Inc. Jun 7, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285176;VEM US;10015847 | $28.00 |
| Gilead Sciences, Inc. Jun 7, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285248;VEM US;10015847 | $21.42 |
| Gilead Sciences, Inc. Jun 6, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285113;VEM US;10015847 | $41.98 |
| Mirum Pharmaceuticals, Inc. Jun 3, 2025 | Travel and Lodging travel to SAN DIEGO, CA | $1,675 |
| Mirum Pharmaceuticals, Inc. Jun 3, 2025 | Travel and Lodging travel to SAN DIEGO, CA | $622 |
| Mirum Pharmaceuticals, Inc. Jun 3, 2025 | Education | $340 |
| Mirum Pharmaceuticals, Inc. Jun 3, 2025 | Travel and Lodging travel to SAN DIEGO, CA | $120 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $11,040 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $1,143 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $203 |
| Gilead Sciences, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4111778;AHM;10015847 | $4,930 |
| Gilead Sciences, Inc. May 7, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to McLean, VA · in-kind Company’s description;4327691;AHM;10015847 | $971 |
| Intra-sana Laboratories Apr 30, 2025 | Honoraria RELTONE 200 MG; GLYCATE; RELTONE 400 MG · GALLSTONES | $1,500 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee Livmarli · Alagille syndrome | $5,200 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Chicago, IL | $702 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Chicago, IL | $512 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Chicago, IL | $113 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Chicago, IL | $54.00 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Chicago, IL | $50.12 |
| Mirum Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging Livmarli · Alagille syndrome · travel to Chicago, IL | $10.71 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $6,200 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $784 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL | $98.82 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $49.00 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $357 |
| Ipsen Biopharmaceuticals, Inc Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) Bylvay · Gastroenterology | $4,590 |
| Ipsen Biopharmaceuticals, Inc Mar 22, 2025 | Compensation for services other than consulting (speaking, faculty) Bylvay · Gastroenterology | $2,754 |
| Fujifilm Healthcare Americas Corporation Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) UTASWAKO AFP-L3 · Medical Device | $3,948 |
| Fujifilm Healthcare Americas Corporation Mar 21, 2025 | Travel and Lodging UTASWAKO AFP-L3 · Medical Device · travel to Metairie, LA | $585 |
| Gilead Sciences, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4119625;AHM;10015847 | $1,895 |
| Mirum Pharmaceuticals, Inc. Mar 12, 2025 | Consulting Fee Livmarli · Alagille syndrome | $1,540 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026678;GTF;10015847 | $284 |
| Histosonics, Inc. Feb 11, 2025 | Travel and Lodging travel to Plymouth, MN | $241 |
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Consulting Fee | $1,343 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $10,557 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $995 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $299 |
| Ipsen Biopharmaceuticals, Inc Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Madrigal Pharmaceuticals Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,993 |
| Madrigal Pharmaceuticals Jan 28, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to MONTGOMERY, OH · in-kind | $606 |
| Madrigal Pharmaceuticals Jan 28, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to MONTGOMERY, OH · in-kind | $253 |
| Madrigal Pharmaceuticals Jan 28, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to MONTGOMERY, OH | $152 |
| Eisai Inc. Jan 16, 2025 | Education Lenvima · Oncology | $317 |
| Madrigal Pharmaceuticals Jan 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,410 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Consulting Fee | $1,880 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $1,198,805 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - Study to check the safety of fazirsiran and learn if fazirsiran can help people with liver disease and scarring (fibrosis) due to an abnormal version of ALPHA-1 antitrypsin protein
Takeda Pharmaceuticals U.S.A., Inc. - A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)…
Gilead Sciences, Inc. - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Ipsen Bioscience Inc. · Active, not recruiting · NCT05627362 - A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Ipsen Bioscience Inc. · Completed · NCT06383403 - A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC
Genentech, Inc. - A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. - A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Ipsen Pharma Sas · Active, not recruiting · NCT06447168
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.